FTSE 100 pharma giant GSK kicks off Zantac appeal as company seeks to limit damages pharma GSK has launched an appeal against the Delaware Superior Court's recent so-called Daubert ruling.
GSK shares drag the FTSE 100 as company faces muli-billion pound bill after Zantac trial ruling pharma GSK has hit back against a US ruling that found it could be sued over the potential cancer-causing properties of its heartburn drug Zantac.
GSK: How much could the Zantac lawsuits cost? Pharma Last month, Shore Capital analysts estimated that up to $30bn (£24bn) for litigation was already priced into GSK’s shares.
GSK: Cancer claims plague pharma giant as it settles another Zantac case February 29, 2024 GSK has reached another confidential settlement in a Californian lawsuit that had alleged its best-selling indigestion drug, Zantac, was carcinogenic.